Please note that slides are for review only and not to be repurposed or published.

Data + Perspectives: Clinical Investigators Explore the Emerging Role of PARP Inhibition in the Management of Breast Cancer

MODULE 1:
Biologic Rationale for PARP Inhibition; Indications for BRCA and Multigene Panel Testing in Patients with Breast Cancer — Dr Domchek

MODULE 2:
Available Research with and Potential Clinical Role of Olaparib in Metastatic Breast Cancer — Dr Robson

MODULE 3:
Clinical Database with and Ongoing Evaluation of Other PARP Inhibitors in Breast Cancer — Dr Rugo

MODULE 4:
Prevention, Recognition and Management of Toxicities Associated with PARP Inhibitors in Breast Cancer — Dr Gelmon

Cases from the Community: Clinical Investigators Provide Their Perspectives on Actual Breast Cancer Cases and the Implications of Emerging Research

MODULE 1:
Management of Newly Diagnosed Localized HER2-Positive Disease — Dr Blackwell

MODULE 2:
Use of Genomic Assays to Assist in Clinical Decision-Making for Patients with ER-Positive Early Breast Cancer — Dr Sledge

MODULE 3:
Selection and Sequence of Therapy for Patients with ER-Positive, HER2-Negative Metastatic Breast Cancer (mBC) — Dr Tolaney

MODULE 4:
Protocol and Off-Protocol Decision-Making for Patients with HER2-Positive mBC — Dr Miller

MODULE 5:
Novel Targeted Agents and Other Emerging Therapeutic Strategies — Dr O’Shaughnessy